ACEIs and ARBs in Renal Protection

Guideline-Based Equivalence

The American Diabetes Association recommends using either ACEIs or ARBs as first-line therapy for hypertension in patients with albuminuria, without preferential recommendation of one class over the other 2
The choice between ACEIs and ARBs should be based primarily on tolerability rather than efficacy differences for patients with albuminuria (UACR ≥30 mg/g) 2, 3

Reduction of intraglomerular pressure by preferentially dilating efferent arterioles decreases glomerular capillary pressure and proteinuria independent of systemic blood pressure effects 4
Decreased albuminuria and slowed GFR decline in patients with established CKD, particularly those with diabetes and macroalbuminuria 4

The CREDENCE trial demonstrated that both ACEIs and ARBs serve as appropriate foundation therapy for renal protection, with >99% of participants taking either an ACE inhibitor or ARB 1, 2
Guidelines consistently group ACEIs and ARBs together as "RAS inhibitors" when discussing renal protection strategies, reflecting their equivalent clinical utility 2, 4

Initiate either an ACEI or ARB at standard starting dose when albuminuria is present (UACR ≥30 mg/g) 2, 3
Titrate to maximum tolerated dose indicated for blood pressure treatment, as clinical trials demonstrating efficacy used maximal dosing 4, 5
Monitor serum creatinine/eGFR and potassium within 2-4 weeks of initiation or dose change, then at least annually 3, 6

Never combine ACE inhibitors and ARBs, as multiple clinical trials have demonstrated higher adverse event rates without additional benefits on cardiovascular or CKD outcomes 3, 4, 5, 6
Do not underdose these medications, as clinical trials demonstrating efficacy used maximum tolerated doses 4
Monitor for hyperkalemia risk, especially with coadministration of potassium-sparing diuretics, NSAIDs, or mineralocorticoid receptor antagonists, and in patients with reduced eGFR (<60 mL/min/1.73 m²) 3, 6

Both drug classes can be continued even as kidney function declines to eGFR <30 mL/min/1.73 m², as they may provide cardiovascular benefit without significantly increasing the risk of end-stage kidney disease 3, 5